Observational Assessment of Long Term Outcomes on Entecavir

This is a study to assess the rates of the following clinical outcomes:

1. Malignant neoplasms (overall and non-HCC, in each case including carcinoma in situ [CIS] but excluding non-melanoma skin cancer, and HCC).
2. Liver-related events of HBV disease progression.
3. Mortality (all cause, liver-related).

You may be eligible for this study if you have:

• Chronic HBV infection
• HBV nucleoside/tide-naïve or –experienced
• No prior treatment with ETV (entecavir)

For more information, please call the number below.